Durable Efficacy of Alemtuzumab in Relapsing-Remitting Multiple Sclerosis Patients Who Participated in the CARE-MS Studies: Three Year Follow-Up (S41.001) - Concepedia

Concepedia

Publication | Closed Access

Durable Efficacy of Alemtuzumab in Relapsing-Remitting Multiple Sclerosis Patients Who Participated in the CARE-MS Studies: Three Year Follow-Up (S41.001)

13

Citations

0

References

2013

Year

Edward Fox, Douglas L. Arnold, Jeffrey Cohen, Alasdair Coles, Christian Confavreux, Hans Hartung, Eva Havrdová, Krzysztof Selmaj, Howard L. Weiner, Cary Twyman,

Abstract

OBJECTIVE: To examine durability of alemtuzumab's efficacy in relapsing-remitting multiple sclerosis (RRMS) patients who participated in the pivotal phase 3 CARE-MS trials and continued in the extension study.